Optimal Design in Population Kinetic Experiments by Set-Valued Methods Peter GennemarkAlexander DanisWarwick Tucker Research Article 15 July 2011 Pages: 495 - 507
Bayesian Quantitative Disease–Drug–Trial Models for Parkinson’s Disease to Guide Early Drug Development Joo Yeon LeeJogarao V. S. Gobburu Research Article 27 July 2011 Pages: 508 - 518
BDDCS Applied to Over 900 Drugs Leslie Z. BenetFabio BroccatelliTudor I. Oprea Research Article 05 August 2011 Pages: 519 - 547
Differential Metabolism of Organic Nitrates by Aldehyde Dehydrogenase 1a1 and 2: Substrate Selectivity, Enzyme Inactivation, and Active Cysteine Sites Pei-Suen TsouNathaniel A. PageHo-Leung Fung Research Article 05 August 2011 Pages: 548 - 555
Harmonization of Regulatory Approaches for Evaluating Therapeutic Equivalence and Interchangeability of Multisource Drug Products: Workshop Summary Report Mei-Ling ChenVinod P. ShahLawrence X. Yu Meeting Report 16 August 2011 Pages: 556 - 564
Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans Cheng ChangWonkyung ByonTristan S. Maurer Research Article 17 August 2011 Pages: 565 - 575
Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology Tristan S. MaurerAvijit GhoshRalph P. Robinson Research Article 26 August 2011 Pages: 576 - 584
Relationships between Liposome Properties, Cell Membrane Binding, Intracellular Processing, and Intracellular Bioavailability Yinghuan LiJie WangJessie L.-S. Au Research Article 10 September 2011 Pages: 585 - 597
Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy Dinko RekićOskar CleweMichael Ashton Research Article 13 September 2011 Pages: 598 - 605
Epigenetic CpG Demethylation of the Promoter and Reactivation of the Expression of Neurog1 by Curcumin in Prostate LNCaP Cells Limin ShuTin Oo KhorAh-Ng Tony Kong Research Article 22 September 2011 Pages: 606 - 614
Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity—An Overview for Applied Toxicology Tobias Christian FuchsPhilip Hewitt Review Article 04 October 2011 Pages: 615 - 631
Factors Influencing the Use and Interpretation of Animal Models in the Development of Parenteral Drug Delivery Systems Marilyn N. Martinez Review Article 05 October 2011 Pages: 632 - 649
Comparative Performance of Cell Life Span and Cell Transit Models for Describing Erythropoietic Drug Effects Nageshwar R. BudhaAndreas KovarBernd Meibohm Research Article 18 October 2011 Pages: 650 - 661
Holford NHG and Sheiner LB “Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models”, Clin Pharmacokin 6:429–453 (1981)—The Backstory Nick Holford Commentary 18 October 2011 Pages: 662 - 664
Population Pharmacokinetics of Telapristone (CDB-4124) and its Active Monodemethylated Metabolite CDB-4453, with a Mixture Model for Total Clearance Denise MorrisJoseph PodolskiLawrence Fleckenstein Research Article Open access 25 October 2011 Pages: 665 - 673
Erratum to: Modeling the Effects of Vaccination and Treatment on Pandemic Influenza Zhilan FengSherry TowersYiding Yang Erratum 18 October 2011 Pages: 674 - 674